To identify those miRNAs that were aberrantly expressed in CML LSCs through a BCR-ABL-independent mechanism, we selected miRNAs whose expression did not change after IM treatment. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.